Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer’s disease trial
INTRODUCTION In trials of amyloid-lowering drugs for Alzheimer’s disease (AD), differential eligibility may contribute to under-inclusion of racial and ethnic underrepresented groups. We examined pl…